Breast cancer: New paradigms Conference Paper

  


Author: Offit, K.
Title: Breast cancer: New paradigms
Conference Title: 25th National Meeting of the Clinical Ligand Assay Society
Abstract: One of the most challenging developments in clinical oncology is the availability of testing for inherited mutations of cancer predisposition genes. As these genes were identified and characterized, guidelines for the responsible clinical translation of this information were developed by medical and surgical subspecialty societies (e.g., Statement of the American Society of Clinical Oncology, 1996). Each guideline emphasized that in the process of offering a predictive genetic 'test' to a patient or family affected by cancer, the provider and the individual being tested must be prepared to deal with all the medical, psychological, and social consequences of a positive, negative, or ambiguous result. This presentation focuses on the genetics of breast cancer predisposition. AH genetic testing, however, must be offered in the context of informed consent, reviewed elsewhere (1).
Keywords: gene mutation; cancer risk; conference paper; cancer susceptibility; gene product; practice guideline; brca1 protein; brca2 protein; heterozygote; protein p53; breast carcinoma; ovary carcinoma; informed consent; human
Journal Title Journal of Clinical Ligand Assay
Volume: 22
Issue: 2
Conference Dates: 1999 May 5-8
Conference Location: Philadelphia, PA
ISBN: 1081-1672
Publisher: Clinical Ligand Assay Society  
Date Published: 1999-06-01
Start Page: 217
End Page: 220
Language: English
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032878480&partnerID=40&md5=b168dd09d325ffab307f5055977bf75e
Notes: Conference Paper -- Export Date: 16 August 2016 -- Source: Scopus